Aric G. Colunga, Ph.D.
Affiliations: | 2012 | Molecular Medicine | University of Maryland School of Medicine, Baltimore, MD, United States |
Area:
Virology Biology, Cell Biology, ImmunologyGoogle:
"Aric Colunga"Mean distance: 30533.1
Parents
Sign in to add mentor| Laure Aurelian | grad student | 2012 | University of Maryland Medical School | |
| (Molecular Mechanisms of Oncolysis by the Herpes Simplex Virus Type 2 Mutant DeltaPK.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Paulson KG, Voillet V, McAfee MS, et al. (2018) Acquired cancer resistance to combination immunotherapy from transcriptional loss of class I HLA. Nature Communications. 9: 3868 |
| Colunga A, Pulliam T, Nghiem P. (2017) Merkel Cell Carcinoma in the Age of Immunotherapy: Facts and Hopes. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 24: 2035-2043 |
| Aurelian L, Bollino D, Colunga A. (2016) The oncolytic virus ΔPK has multi-modal anti-tumor activity. Pathogens and Disease |
| Bollino D, Colunga A, Li B, et al. (2015) ∆PK oncolytic activity includes modulation of tumor cell milieu. The Journal of General Virology |
| Colunga A, Bollino D, Schech A, et al. (2014) Calpain-dependent clearance of the autophagy protein p62/SQSTM1 is a contributor to ΔpK oncolytic activity in melanoma Gene Therapy. 21: 371-378 |
| Colunga A, Li B, Aurelian L. (2011) Abstract 600: The HSV-2 oncolytic virus ΔPK induces multiple death and inflammatory programs associated with inhibition of melanoma tumor growth Cancer Research. 71: 600-600 |
| Colunga AG, Laing JM, Aurelian L. (2010) The HSV-2 mutant DeltaPK induces melanoma oncolysis through nonredundant death programs and associated with autophagy and pyroptosis proteins. Gene Therapy. 17: 315-27 |
| Poff JA, Allen CT, Traughber B, et al. (2008) Pulsed high-intensity focused ultrasound enhances apoptosis and growth inhibition of squamous cell carcinoma xenografts with proteasome inhibitor bortezomib. Radiology. 248: 485-91 |